Akihiro Tamiya

8PUBLICATIONS
36CO-AUTHORS
Molecular targetsPredictive and prognostic markersPeripheral nervous systemCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 30, 2026
Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama

|Apr 05, 2025
Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study.

Akihiro Tamiya, Yasuyuki Mizumori, Mitsuo Osuga

|Nov 04, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura

|Jan 06, 2022
Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.

Yusuke Murakami, Akihiro Tamiya, Yoshihiko Taniguchi

|Feb 06, 2020
Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study.

Akihiro Tamiya, Yasuhiro Koh, Shun-Ichi Isa

|Dec 28, 2019
Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.

Yuichi Adachi, Akihiro Tamiya, Yoshihiko Taniguchi

Pageof 2

Frequent Collaborators

2 joint publications

Yasuhiro Koh

1 joint publications

Shinji Kobuchi

1 joint publications

Yuichi Adachi

1 joint publications

Yuki Katayama